Evolutionary Analysis of Human Immunodeficiency Virus Type 1 Therapies Based on Conditionally Replicating Vectors

PLoS Computational Biology

Volumn 8, Issue 10, 2012, Pages

  Ke, Ruian ^a   Lloyd Smith, James O ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DYNAMICS; GENE THERAPY; RANDOM PROCESSES; STOCHASTIC MODELS; VECTORS; VIRUSES;

ANTI-VIRAL DRUGS; CO-EVOLUTIONARY; COMPUTATIONAL MODELLING; DETERMINISTICS; EVOLUTIONARY DYNAMICS; EVOLVED RESISTANCES; HUMAN IMMUNODEFICIENCY VIRUS; KEEP TRACK OF; REPLICATING VECTORS; VIRAL LOAD;

STOCHASTIC SYSTEMS;

EID: 84868137431     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002744     Document Type: Article

References (86)

1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657-666.
2. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643-656.
3. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
5. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11: 750-759.
6. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394.
7. Carr A, Cooper DA, (2000) Adverse effects of antiretroviral therapy. Lancet 356: 1423-1430.
8. Barouch DH, (2008) Challenges in the development of an HIV-1 vaccine. Nature 455: 613-619.
9. Rossi JJ, June CH, Kohn DB, (2007) Genetic therapies against HIV. Nat Biotechnol 25: 1444-1454.
10. Mautino MR, (2002) Lentiviral vectors for gene therapy of HIV-1 infection. Curr Gene Ther 2: 23-43.
11. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, et al. (2004) Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 78: 2601-2605.
12. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
13. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571.
14. Larder BA, Kellam P, Kemp SD, (1993) Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365: 451-453.
15. Larder BA, Kemp SD, (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
16. Dropulic B, Hermankova M, Pitha PM, (1996) A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A 93: 11103-11108.
17. Nelson GW, Perelson AS, (1995) Modeling defective interfering virus therapy for AIDS: conditions for DIV survival. Math Biosci 125: 127-153.
18. Woffendin C, Yang ZY, Udaykumar, Xu L, Yang NS, et al. (1994) Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci U S A 91: 11581-11585.
19. Turner AM, De La Cruz J, Morris KV, (2009) Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression. Mol Ther 17: 360-368.
20. Zeng L, Planelles V, Sui Z, Gartner S, Maggirwar SB, et al. (2006) HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1. J Gene Med 8: 18-28.
21. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377.
22. Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, et al. (2004) Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 9: 902-913.
23. Morris KV, Looney DJ, (2005) Characterization of human immunodeficiency virus (HIV)-2 vector mobilization by HIV-1. Hum Gene Ther 16: 1463-1472.
24. Li D, Lott WB, Lowry K, Jones A, Thu HM, et al. (2011) Defective interfering viral particles in acute dengue infections. PLoS One 6: e19447.
25. Marriott AC, Dimmock NJ, (2010) Defective interfering viruses and their potential as antiviral agents. Rev Med Virol 20: 51-62.
26. Stauffer Thompson KA, Rempala GA, Yin J, (2009) Multiple-hit inhibition of infection by defective interfering particles. J Gen Virol 90: 888-899.
27. Garcia-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarmis C, (2004) Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol 78: 11678-11685.
28. Holland JJ (1990) Generation and replication of defective viral genomes. In: Fields BN, Knipe DM, editors. Fields Virology. 2nd ed. New York: Raven Press. pp. 77-99.
29. Huang AS, Baltimore D, (1970) Defective viral particles and viral disease processes. Nature 226: 325-327.
30. Metzger VT, Lloyd-Smith JO, Weinberger LS, (2011) Autonomous targeting of infectious superspreaders using engineered transmissible therapies. PLoS Comput Biol 7: e1002015.
31. Garcia-Arriaza J, Ojosnegros S, Davila M, Domingo E, Escarmis C, (2006) Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol 360: 558-572.
32. DePolo NJ, Giachetti C, Holland JJ, (1987) Continuing coevolution of virus and defective interfering particles and of viral genome sequences during undiluted passages: virus mutants exhibiting nearly complete resistance to formerly dominant defective interfering particles. J Virol 61: 454-464.
33. O'Hara PJ, Nichol ST, Horodyski FM, Holland JJ, (1984) Vesicular stomatitis virus defective interfering particles can contain extensive genomic sequence rearrangements and base substitutions. Cell 36: 915-924.
34. Horiuchi K, (1983) Co-evolution of a filamentous bacteriophage and its defective interfering particles. J Mol Biol 169: 389-407.
35. ter Brake O, t Hooft K, Liu YP, Centlivre M, von Eije KJ, et al. (2008) Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 16: 557-564.
36. Porco TC, Lloyd-Smith JO, Gross KL, Galvani AP, (2005) The effect of treatment on pathogen virulence. J Theor Biol 233: 91-102.
37. Weinberger LS, Schaffer DV, Arkin AP, (2003) Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol 77: 10028-10036.
38. Nowak MA, May RM (2000) Virus dynamics: mathematical principles of immunology and virology. Oxford, England: Oxford University Press. 256 p.
39. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
40. Nowak MA, May RM, Anderson RM, (1990) The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. Aids 4: 1095-1103.
41. Althaus CL, De Boer RJ, (2008) Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol 4: e1000103.
42. Wodarz D, Nowak MA, (1999) Dynamics of immune escape in HIV infection. Wien Klin Wochenschr 111: 419-427.
43. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG, et al. (1995) Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375: 606-611.
44. Ribeiro RM, Bonhoeffer S, (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci U S A 97: 7681-7686.
45. Bonhoeffer S, Nowak MA, (1997) Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Biol Sci 264: 631-637.
46. DiGiusto DL, Krishnan A, Li L, Li H, Li S, et al. (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2: 36ra43.
47. Mautino MR, Morgan RA, (2002) Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care STDS 16: 11-26.
48. Li MJ, Kim J, Li S, Zaia J, Yee JK, et al. (2005) Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 12: 900-909.
49. Alizon S, van Baalen M, (2008) Multiple infections, immune dynamics, and the evolution of virulence. Am Nat 172: E150-168.
50. Aviran S, Shah PS, Schaffer DV, Arkin AP, (2010) Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles. PLoS Comput Biol 6: e1000883.
51. Diekmann O, Heesterbeek JA, Roberts MG, (2010) The construction of next-generation matrices for compartmental epidemic models. J R Soc Interface 7: 873-885.
52. Vijh S, Pilip IM, Pamer EG, (1998) Effect of antigen-processing efficiency on in vivo T cell response magnitudes. J Immunol 160: 3971-3977.
53. Schneider RJ, Shenk T, (1987) Impact of virus infection on host cell protein synthesis. Annu Rev Biochem 56: 317-332.
54. Ball CL, Gilchrist MA, Coombs D, (2007) Modeling within-host evolution of HIV: mutation, competition and strain replacement. Bull Math Biol 69: 2361-2385.
55. Gilchrist MA, Coombs D, Perelson AS, (2004) Optimizing within-host viral fitness: infected cell lifespan and virion production rate. J Theor Biol 229: 281-288.
56. Moore MD, Fu W, Nikolaitchik O, Chen J, Ptak RG, et al. (2007) Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. J Virol 81: 4002-4011.
57. Clever JL, Parslow TG, (1997) Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J Virol 71: 3407-3414.
58. Berkhout B, van Wamel JL, (1996) Role of the DIS hairpin in replication of human immunodeficiency virus type 1. J Virol 70: 6723-6732.
59. Althaus CL, De Boer RJ, (2012) Impaired immune evasion in HIV through intracellular delays and multiple infection of cells. Proc Biol Sci 279: 3003-10.
60. Josefsson L, King MS, Makitalo B, Brannstrom J, Shao W, et al. (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A 108: 11199-11204.
61. Henderson GJ, Lee SK, Irlbeck DM, Harris J, Kline M, et al. (2012) Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob Agents Chemother 56: 623-633.
62. Sanjuan R, (2010) Mutational fitness effects in RNA and single-stranded DNA viruses: common patterns revealed by site-directed mutagenesis studies. Philos Trans R Soc Lond B Biol Sci 365: 1975-1982.
63. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, et al. (2009) Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 5: e1000365.
64. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, et al. (2002) Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76: 1753-1761.
65. Weissman DB, Desai MM, Fisher DS, Feldman MW, (2009) The rate at which asexual populations cross fitness valleys. Theor Popul Biol 75: 286-300.
66. Iwasa Y, Michor F, Nowak MA, (2004) Stochastic tunnels in evolutionary dynamics. Genetics 166: 1571-1579.
67. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ, (2004) Evidence for positive epistasis in HIV-1. Science 306: 1547-1550.
68. Woolhouse ME, Webster JP, Domingo E, Charlesworth B, Levin BR, (2002) Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet 32: 569-577.
69. Funk GA, Oxenius A, Fischer M, Opravil M, Joos B, et al. (2006) HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. J Med Virol 78: 1141-1146.
70. Wong JK, Strain MC, Porrata R, Reay E, Sankaran-Walters S, et al. (2010) In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog 6: e1000748.
71. Klatt NR, Shudo E, Ortiz AM, Engram JC, Paiardini M, et al. (2010) CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 6: e1000747.
72. Thompson KA, Yin J, (2010) Population dynamics of an RNA virus and its defective interfering particles in passage cultures. Virol J 7: 257.
73. Scott PD, Meng B, Marriott AC, Easton AJ, Dimmock NJ, (2011) Defective interfering influenza virus confers only short-lived protection against influenza virus disease: evidence for a role for adaptive immunity in DI virus-mediated protection in vivo. Vaccine 29: 6584-6591.
74. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
75. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, et al. (2002) Recombination: Multiply infected spleen cells in HIV patients. Nature 418: 144.
76. Aaskov J, Buzacott K, Thu HM, Lowry K, Holmes EC, (2006) Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science 311: 236-238.
77. Kirkwood TB, Bangham CR, (1994) Cycles, chaos, and evolution in virus cultures: a model of defective interfering particles. Proc Natl Acad Sci U S A 91: 8685-8689.
78. Szathmary E, (1993) Co-operation and defection: playing the field in virus dynamics. J Theor Biol 165: 341-356.
79. Szathmary E, (1992) Natural selection and dynamical coexistence of defective and complementing virus segments. J Theor Biol 157: 383-406.
80. Read AF, Lynch PA, Thomas MB, (2009) How to make evolution-proof insecticides for malaria control. PLoS Biol 7: e1000058.
81. Coombs D, Gilchrist MA, Percus J, Perelson AS, (2003) Optimal viral production. Bull Math Biol 65: 1003-1023.
82. Phillips AN, (1996) Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 271: 497-499.
83. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, et al. (2001) Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 194: 1277-1287.
84. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, et al. (1996) Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274: 985-989.
85. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
86. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354: 1782-1785.